È possibile coniugare risparmio e miglioramento nelle aziende USL?
The present study aimed to evaluate if it’s possible to reduce the costs for the anti-infective medicine in a ward for the infectious disease. Analytic accounts data, related to the cost for three kind of drugs (antibiotic, antimicrobic and antriretroviral) will be presented. The analytic account is...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SEEd Medical Publishers
2000-06-01
|
| Series: | Farmeconomia: Health Economics and Therapeutic Pathways |
| Online Access: | https://journals.seedmedicalpublishers.com/index.php/FE/article/view/713 |
| _version_ | 1811289352545763328 |
|---|---|
| author | Sergio Sabbatani |
| author_facet | Sergio Sabbatani |
| author_sort | Sergio Sabbatani |
| collection | DOAJ |
| description | The present study aimed to evaluate if it’s possible to reduce the costs for the anti-infective medicine in a ward for the infectious disease. Analytic accounts data, related to the cost for three kind of drugs (antibiotic, antimicrobic and antriretroviral) will be presented. The analytic account is referred to the Bologna USL Firm (Presidi ospedalieri Bellaria and Maggiore) and to the Hospital Unit for the infectious disease (Ospedale Maggiore) in the year 1999. The Hospital Unit for the infectious disease consists of two ward for day of stay (32 beds), one day hospital for 10 beds and one divisional outpatients’ clinic. In 1999 there were 650 hospitalized (and discharged) patients and 783 day hospital patients. The overall cost for the Bologna USL Firm was L. 11.068.023.000, accounting L. 7.253.846.000 (65.5%) for the antiretroviral drug, L. 1.958.115.000 (17%) for the antibiotic drug and L. 1.856.062.000 (16.8%) for the antimicrobic drug and other antinfective medicine. The expenditure for the Hospital Unit for the infectious disease was L. 7.543.851.000, accounting L. 7.008.163.000 (92.9%) for the antiretroviral drug, L. 256.167.000 (3.4%) for the antibiotic drug and L. 279.521.000 (3.7%) for the antimicrobic drug and other antinfective medicine. |
| first_indexed | 2024-04-13T03:53:22Z |
| format | Article |
| id | doaj.art-94ff673cbd2d4d25bc25ecc50b926be0 |
| institution | Directory Open Access Journal |
| issn | 2240-256X |
| language | English |
| last_indexed | 2024-04-13T03:53:22Z |
| publishDate | 2000-06-01 |
| publisher | SEEd Medical Publishers |
| record_format | Article |
| series | Farmeconomia: Health Economics and Therapeutic Pathways |
| spelling | doaj.art-94ff673cbd2d4d25bc25ecc50b926be02022-12-22T03:03:44ZengSEEd Medical PublishersFarmeconomia: Health Economics and Therapeutic Pathways2240-256X2000-06-01129710110.7175/fe.v1i2.713660È possibile coniugare risparmio e miglioramento nelle aziende USL?Sergio Sabbatani0Unità Operativa di Malattie Infettive Osp. Maggiore Bologna
The present study aimed to evaluate if it’s possible to reduce the costs for the anti-infective medicine in a ward for the infectious disease. Analytic accounts data, related to the cost for three kind of drugs (antibiotic, antimicrobic and antriretroviral) will be presented. The analytic account is referred to the Bologna USL Firm (Presidi ospedalieri Bellaria and Maggiore) and to the Hospital Unit for the infectious disease (Ospedale Maggiore) in the year 1999. The Hospital Unit for the infectious disease consists of two ward for day of stay (32 beds), one day hospital for 10 beds and one divisional outpatients’ clinic. In 1999 there were 650 hospitalized (and discharged) patients and 783 day hospital patients. The overall cost for the Bologna USL Firm was L. 11.068.023.000, accounting L. 7.253.846.000 (65.5%) for the antiretroviral drug, L. 1.958.115.000 (17%) for the antibiotic drug and L. 1.856.062.000 (16.8%) for the antimicrobic drug and other antinfective medicine. The expenditure for the Hospital Unit for the infectious disease was L. 7.543.851.000, accounting L. 7.008.163.000 (92.9%) for the antiretroviral drug, L. 256.167.000 (3.4%) for the antibiotic drug and L. 279.521.000 (3.7%) for the antimicrobic drug and other antinfective medicine.https://journals.seedmedicalpublishers.com/index.php/FE/article/view/713 |
| spellingShingle | Sergio Sabbatani È possibile coniugare risparmio e miglioramento nelle aziende USL? Farmeconomia: Health Economics and Therapeutic Pathways |
| title | È possibile coniugare risparmio e miglioramento nelle aziende USL? |
| title_full | È possibile coniugare risparmio e miglioramento nelle aziende USL? |
| title_fullStr | È possibile coniugare risparmio e miglioramento nelle aziende USL? |
| title_full_unstemmed | È possibile coniugare risparmio e miglioramento nelle aziende USL? |
| title_short | È possibile coniugare risparmio e miglioramento nelle aziende USL? |
| title_sort | e possibile coniugare risparmio e miglioramento nelle aziende usl |
| url | https://journals.seedmedicalpublishers.com/index.php/FE/article/view/713 |
| work_keys_str_mv | AT sergiosabbatani epossibileconiugarerisparmioemiglioramentonelleaziendeusl |